Back to Search Start Over

Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020.

Authors :
Bogogiannidou Z
Speletas M
Vontas A
Nikoulis DJ
Dadouli K
Kyritsi MA
Mouchtouri VA
Mina P
Anagnostopoulos L
Koureas M
Karavasilis V
Nikou O
Pinaka O
Thomaidis PC
Kadoglou K
Bedevis K
Spyrou N
Eleftheriou AA
Papaevangelou V
Gikas A
Vatopoulos A
Ntzani EE
Prezerakos P
Tsiodras S
Hadjichristodoulou C
Source :
Vaccines [Vaccines (Basel)] 2021 May 13; Vol. 9 (5). Date of Electronic Publication: 2021 May 13.
Publication Year :
2021

Abstract

A serosurvey of IgG antibodies against SARS-CoV-2 was conducted in Greece between May and August 2020. It was designed as a cross-sectional survey and was repeated at monthly intervals. The leftover sampling methodology was used and a geographically stratified sampling plan was applied. Of 20,110 serum samples collected, 89 (0.44%) were found to be positive for anti-SARS-CoV-2 antibodies, with higher seroprevalence (0.35%) observed in May 2020. The highest seroprevalence was primarily observed in the "30-49" year age group. Females presented higher seroprevalence compared to males in May 2020 (females: 0.58% VS males: 0.10%). This difference reversed during the study period and males presented a higher proportion in August 2020 (females: 0.12% VS males: 0.58%). Differences in the rate of seropositivity between urban areas and the rest of the country were also observed during the study period. The four-month infection fatality rate (IFR) was estimated to be 0.47%, while the respective case fatality rate (CFR) was at 1.89%. Our findings confirm low seroprevalence of COVID-19 in Greece during the study period. The young adults are presented as the most affected age group. The loss of the cumulative effect of seropositivity in a proportion of previous SARS-CoV-2 infections was indicated.

Details

Language :
English
ISSN :
2076-393X
Volume :
9
Issue :
5
Database :
MEDLINE
Journal :
Vaccines
Publication Type :
Academic Journal
Accession number :
34068100
Full Text :
https://doi.org/10.3390/vaccines9050504